CAJ | 학술논문

目的：研究探讨孟鲁司特对过敏性紫癜患儿血浆细胞因子水平的影响及其临床疗效。方法：选取本院收治的过敏性紫癜患儿100例作为研究对象，将其随机分为两组，每组各50例患者，对照组患儿给予抗组胺类药物、抗感染类药物以及钙剂、维生素C等常规的治疗药物，观察组患者在常规治疗的基础上给予孟鲁司特咀嚼片治疗。以两周为一个疗程，比较两组患者治疗前后的血浆细胞因子水平，观察其临床治疗效果。结果：观察组和对照组患者治疗前的IL-6、IL-8和TNF-α表达水平差异均无统计学意义（P>0.05）；治疗后，三项指标的表达水平都有显著降低，且与治疗前相比差异均有统计学意义（P<0.05）；观察组患者各项指标的下降程度超过对照组患者，两组比较差异具有统计意义（P<0.05）。观察组和对照组患者的临床治疗总有效率分别是96.0%和78.0%，两组比较差异有统计学意义（P<0.05）。结论：孟鲁司特治疗儿童过敏性紫癜具有临床疗效确切、安全性好的优点，可以对患儿血浆内的细胞因子进行调节，促进患儿免疫功能的改善，值得临床推广应用。
목적：연구탐토맹로사특대과민성자전환인혈장세포인자수평적영향급기림상료효。방법：선취본원수치적과민성자전환인100례작위연구대상，장기수궤분위량조，매조각50례환자，대조조환인급여항조알류약물、항감염류약물이급개제、유생소C등상규적치료약물，관찰조환자재상규치료적기출상급여맹로사특저작편치료。이량주위일개료정，비교량조환자치료전후적혈장세포인자수평，관찰기림상치료효과。결과：관찰조화대조조환자치료전적IL-6、IL-8화TNF-α표체수평차이균무통계학의의（P>0.05）；치료후，삼항지표적표체수평도유현저강저，차여치료전상비차이균유통계학의의（P<0.05）；관찰조환자각항지표적하강정도초과대조조환자，량조비교차이구유통계의의（P<0.05）。관찰조화대조조환자적림상치료총유효솔분별시96.0%화78.0%，량조비교차이유통계학의의（P<0.05）。결론：맹로사특치료인동과민성자전구유림상료효학절、안전성호적우점，가이대환인혈장내적세포인자진행조절，촉진환인면역공능적개선，치득림상추엄응용。
Objective:To study the clinical efficacy of montelukast in children with allergic purpura of plasma cytokine levels .Method:100 children with allergic purpura were selected in our hospital as research subjects,and were randomly divided into two groups,the control group of children were given anti-histamine drugs,anti-infective drugs and calcium,vitamin C and other conventional drugs.The observation group was treated with montelukast chewable tablets treatment on the basis of conventional therapy. In two weeks for a course of treatment,the clinical effect of plasma cytokine levels in patients before and after treatment were compared and observed.Result:IL-6,IL-8 and TNF-αexpression levels observed before the treatment,two groups of patients showed no significant difference(P>0.05);after treatment,the expression levels of three indicators had decreased significantly,and compared with before the treatment,the differences were statistically significant(P<0.05);observation group’ indicators decreased more than control group,the difference was statistically significant(P<0.05).Observation group and control group of patients with clinical response rates were respectively 96.0%and 78.0%,the difference was statistically significant(P<0.05). Conclusion:Montelukast treatment of children with allergic purpura have clinical efficacy,safety,and good benefits, cytokines can be adjusted within the plasma of children,promote the improvement of immune function in children,worthy of clinical application.